Clinical Trials (Phases I–IV)

11+ hour, 29+ min ago   (184+ words) SAN DIEGO, Oct. 11, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, will host an investor call and live webcast to review top-line data…...

11+ hour, 13+ min ago   (349+ words) Viridian Therapeutics issued a press release that announced the positive elegrobart topline results from the phase 3 REVEAL-1 clinical trial in which the drug was evaluated to treat active thyroid eye disease (TED). The trial tested the effects of 2 regimens of…...

16+ hour, 29+ min ago   (187+ words) The data show that the treatment delivers sustained improvements in vision and reduces retinal swelling over a 52-week period. This content was published on Sep 19, 2025 Switzerland’s new process to speed up patient access to the latest drugs hit its first…...

17+ hour, 25+ min ago   (416+ words) ANTIBODIES DESIGNED to recognise more than one target are being explored as potential treatments for chronic rhinosinusitis with nasal polyps, according to a review examining the rationale for broader inflammatory pathway inhibition. The authors consider whether dual- and multispecific antibodies…...

18+ hour, 51+ min ago   (299+ words) Patient preference, comorbidities, and access guide HS treatment selection, Jennifer Hsiao, MD, said at Fall Clinical. With 3 FDA-approved biologics now available for hidradenitis suppurativa (HS), treatment selection comes down to age, patient preference, comorbidities, and access, Jennifer Hsiao, MD, said…...

19+ hour, 27+ min ago   (572+ words) Posted by Defense World Staff on Oct 11th, 2026 The company’s approach centers on INTASYL, a self-delivering short interfering RNA platform designed to silence specific genes. PH-762 targets PD-1, a protein that can inhibit immune-cell activity. By temporarily reducing PD-1 production within…...

19+ hour, 6+ min ago   (47+ words) A new study shows that the dual EZH1/2 inhibitor valemetostat counteracts HTLV-1-induced epigenetic changes in retinal cells and suppresses viral transcription and inflammatory signaling in a model-dependent manner. News Source: Juliet Wilcox. (October 11, 2026). Epigenetic Drug Valemetostat Shows Dual Action Against…...

1+ day, 9+ hour ago   (227+ words) Roche announced positive one-year Phase III trial results for vamikibart, an investigational non-steroid treatment for uveitic macular edema (UME), showing sustained vision improvement and reduced macular swelling. The FDA has accepted Roche's Biologics License Application for vamikibart, with a decision…...

1+ day, 6+ hour ago   (466+ words) HS is frequently misdiagnosed for 7 to 10 years because its symptoms resemble conditions like inflamed epidermal cysts, nodulocystic acne, and furuncles. Table 1. Hurley Staging for Hidradenitis Suppurativa1 Solitary or multiple isolated cysts/abscesses. No scarring or sinus tracts. HS also profoundly affects…...

1+ day, 6+ hour ago   (229+ words) Jennifer Hsiao, MD, explains how defining HS treatment response improves adherence and success. Hsiao, a professor of dermatology at the University of Southern California, where she codirects an HS specialty clinic, drew a contrast with psoriasis and eczema. In those…...